The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Open accessAbstract
Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge in oncology. Here, we proposed molecular pathway-based algorithm for scoring of target drugs using high throughput mutation data to personalize their clinical efficacies. This algorithm was validated on 3,800 exome mutation profiles from The Cancer Genome Atlas (TCGA) project for 128 target drugs. The output values termed Mutational Drug Scores (MDS) showed positive correlation with the published drug efficiencies in clinical trials. We also used MDS approach to simulate all known protein coding genes as the putative drug targets. The model used was built on the basis of 18,273 mutation profiles from COSMIC database for eight cancer types. We found that the MDS algorithm-predicted hits frequently coincide with those already used as targets of the existing cancer drugs, but several novel candidates can be considered promising for further developments. Our results evidence that the MDS is applicable to ranking of anticancer drugs and can be applied for the identification of novel molecular targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“In melanoma, immune checkpoint inhibitors, and anti-BRAF target drugs like Vemurafenib and Dabrafenib dramatically increased the patient’s chances to respond to treatment and to increase survival (Chapman et al., 2011; Prieto et al., 2012).”
BackgroundThe Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
HMDB 4.0: the human metabolome database for 2018
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1089 · Cited by 3,438
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Research works printed but not linked: 8
- Buzdin, 2017, Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs, J. Clin. Oncol., 35, e23142, 10.1200/JCO.2017.35.15_suppl.e23142 · doi:10.1200/jco.2017.35.15_suppl.e23142
- 2017, Leading Causes of Death and Numbers of Deaths, by Sex, Race, and Hispanic Origin: United States, 1980 and 2016
- Hornberger, 2005, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am. J. Manag. Care, 11, 313
- Ko, 2004, Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers, Curr. Pharm. Biotechnol., 5, 459, 10.2174/1389201043376616 · doi:10.2174/1389201043376616
- Petrov, 2017, Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas, Oncotarget, 8, 83768, 10.18632/oncotarget.19662 · doi:10.18632/oncotarget.19662
- Sorokin, 2018, Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation, Oncotarget, 9, 5111, 10.18632/oncotarget.23700 · doi:10.18632/oncotarget.23700
- Wirsching, 2017, Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice, Surgery, 162, 68, 10.1016/j.surg.2017.01.032 · doi:10.1016/j.surg.2017.01.032
- Zhu, 2007, Application of a new probabilistic model for mining implicit associated cancer genes from OMIM and medline, Cancer Inform., 2, 361, 10.1177/117693510600200025 · doi:10.1177/117693510600200025
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?
Deleu, S., Machiels, K., Raes, J., Verbeke, K., & Vermeire, S. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103293 · Cited by 766
The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment
Ornell, F., Moura, H. F., Scherer, J. N., Pechansky, F., Kessler, F. H. P., & von Diemen, L. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113096 · Cited by 308
Jimenez-Lopez, C., Fraga-Corral, M., Carpena, M., García-Oliveira, P., Echave, J., Pereira, A. G., Lourenço-Lopes, C., Prieto, M. A., & Simal-Gandara, J. (2020) · Food & Function · doi:10.1039/d0fo00937g · Cited by 223
Chamorro, F., Carpena, M., Fraga-Corral, M., Echave, J., Riaz Rajoka, M. S., Barba, F. J., Cao, H., Xiao, J., Prieto, M. A., & Simal-Gandara, J. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2021.131315 · Cited by 188
Metadata
- Authors
- Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-23
- Volume
- 10
- Pages
- 1-1
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2912929199
- Cited by
- 531
- References
- 67
- FWCI
- 33.31
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Amazon Web Services
- Microsoft
- Russian Science Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. https://app.cochat.ai/papers/10.3389/fphar.2019.00001
- The paper
- Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019). Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.